Craig W. Lindsley, Ph.D.

University Distinguished Professor

Visit Lab Site

Faculty Appointments
University Distinguished Professor of Pharmacology University Distinguished Professor of ChemistryUniversity Distinguished Professor of BiochemistryWilliam K. Warren, Jr. Chair in Medicine
Ph.D., Chemistry, University of California, Santa Barbara, CaliforniaB.S., Chemistry, California State University, Chico, California
Office Address
1205 Light Hall
Nashville, TN 37232-0697
Research Description
The major focus of the Lindsley laboratory is drug discovery and medicinal chemistry. Students in my lab will collaborate with other members of the Pharmacology, Drug Metabolism and Clinical Pharmacology departments to pursue small molecule hits from high throughput screens, perform lead optimization studies to develop structure-activity-relationships (SAR) and ultimately deliver small molecules with acceptable properties to validate novel targets/mechanisms in in vivo animal models of target diseases. The molecular targets of interest are kinases, GPCRs, ion channels, nuclear hormone receptors and protein-protein interactions, with an emphasis on allosteric modulation as opposed to classical agonism/antagonism. Therapeutic areas of interest span cancer, neuroscience (schizophrenia, anxiety, pain, sleep, Parkinson's disease) and endocrinology (diabetes, obesity). Students will be exposed to every phase of classical drug discovery. As a member of ther Vanderbilt Institutue of Chemical Biology, training in my laboratory will be broad and involve organic synthesis, medicinal chemistry, pharmacology and drug metabolism. For many programs in the neuroscience area, students will have the opportunity to also develop radioligands for binding assay development and PET tracers for imaging studies.

Another focus in the group is parallel synthesis and the development of new technologies for library synthesis. The lab has state-of-the-art microwave synthesis technology, a mass-directed HPLC purification platform and a large collection of monomers and polymer-supported reagents. There are a number of projects directed at synthesizing libraries of small molecule protein-protein inhibitors, target family-directed libraries and other drug-like small molecule libraries for use in high throughput screening efforts.

The third area of interest in my group is synthetic organic chemistry. Students will have the opportunity to work on synthetic methodology projects as well as partial and total synthesis projects.

Research Keywords
Medicinal chemistry efforts to validate novel targets/mechanisms
Sheffler DJ, Williams R, Bridges TM, Xiang Z, Kane AS, Byun NE, Jadhav S, Mock MM, Zheng F, Lewis LM, Jones CK, Niswender CM, Weaver CD, Lindsley CW, Conn PJ. A novel selective muscarinic acetylcholine receptor subtype 1 antagonist reduces seizures without impairing hippocampus-dependent learning. Mol. Pharmacol [print-electronic]. 2009 Aug; 76(2): 356-68. PMID: 19407080, PMCID: PMC2713127, PII: mol.109.056531, DOI: 10.1124/mol.109.056531, ISSN: 1521-0111.

Ayala JE, Chen Y, Banko JL, Sheffler DJ, Williams R, Telk AN, Watson NL, Xiang Z, Zhang Y, Jones PJ, Lindsley CW, Olive MF, Conn PJ. MGluR5 positive allosteric modulators facilitate both hippocampal LTP and LTD and enhance spatial learning. Neuropsychopharmacology [print-electronic]. 2009 Aug; 34(9): 2057-71. PMID: 19295507, PMCID: PMC2884290, PII: npp200930, DOI: 10.1038/npp.2009.30, ISSN: 1740-634X.

Engers DW, Niswender CM, Weaver CD, Jadhav S, Menon UN, Zamorano R, Conn PJ, Lindsley CW, Hopkins CR. Synthesis and evaluation of a series of heterobiarylamides that are centrally penetrant metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulators (PAMs). J. Med. Chem. 2009 Jul 7/23/2009; 52(14): 4115-8. PMID: 19469556, PMCID: PMC2765192, DOI: 10.1021/jm9005065, ISSN: 1520-4804.

Rodriguez AL, Williams R, Zhou Y, Lindsley SR, Le U, Grier MD, Weaver CD, Conn PJ, Lindsley CW. Discovery and SAR of novel mGluR5 non-competitive antagonists not based on an MPEP chemotype. Bioorg. Med. Chem. Lett [print-electronic]. 2009 Jun 6/15/2009; 19(12): 3209-13. PMID: 19443219, PMCID: PMC3177605, PII: S0960-894X(09)00621-0, DOI: 10.1016/j.bmcl.2009.04.110, ISSN: 1464-3405.

Kennedy JP, Conn PJ, Lindsley CW. A novel class of H3 antagonists derived from the natural product guided synthesis of unnatural analogs of the marine bromopyrrole alkaloid dispyrin. Bioorg. Med. Chem. Lett [print-electronic]. 2009 Jun 6/15/2009; 19(12): 3204-8. PMID: 19443215, PII: S0960-894X(09)00618-0, DOI: 10.1016/j.bmcl.2009.04.106, ISSN: 1464-3405.

Bridges TM, Marlo JE, Niswender CM, Jones CK, Jadhav SB, Gentry PR, Plumley HC, Weaver CD, Conn PJ, Lindsley CW. Discovery of the first highly M5-preferring muscarinic acetylcholine receptor ligand, an M5 positive allosteric modulator derived from a series of 5-trifluoromethoxy N-benzyl isatins. J. Med. Chem. 2009 Jun 6/11/2009; 52(11): 3445-8. PMID: 19438238, PMCID: PMC3875304, DOI: 10.1021/jm900286j, ISSN: 1520-4804.

Miller TW, Pérez-Torres M, Narasanna A, Guix M, Stål O, Pérez-Tenorio G, Gonzalez-Angulo AM, Hennessy BT, Mills GB, Kennedy JP, Lindsley CW, Arteaga CL. Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. Cancer Res [print-electronic]. 2009 May 5/15/2009; 69(10): 4192-201. PMID: 19435893, PMCID: PMC2724871, PII: 0008-5472.CAN-09-0042, DOI: 10.1158/0008-5472.CAN-09-0042, ISSN: 1538-7445.

Lavieri R, Scott SA, Lewis JA, Selvy PE, Armstrong MD, Alex Brown H, Lindsley CW. Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part II. Identification of the 1,3,8-triazaspiro[4,5]decan-4-one privileged structure that engenders PLD2 selectivity. Bioorg. Med. Chem. Lett [print-electronic]. 2009 Apr 4/15/2009; 19(8): 2240-3. PMID: 19299128, PMCID: PMC3800051, PII: S0960-894X(09)00246-7, DOI: 10.1016/j.bmcl.2009.02.125, ISSN: 1464-3405.

Lewis JA, Scott SA, Lavieri R, Buck JR, Selvy PE, Stoops SL, Armstrong MD, Brown HA, Lindsley CW. Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part I: Impact of alternative halogenated privileged structures for PLD1 specificity. Bioorg. Med. Chem. Lett [print-electronic]. 2009 Apr 4/1/2009; 19(7): 1916-20. PMID: 19268584, PMCID: PMC3791604, PII: S0960-894X(09)00211-X, DOI: 10.1016/j.bmcl.2009.02.057, ISSN: 1464-3405.

Engers DW, Rodriguez AL, Williams R, Hammond AS, Venable D, Oluwatola O, Sulikowski GA, Conn PJ, Lindsley CW. Synthesis, SAR and unanticipated pharmacological profiles of analogues of the mGluR5 ago-potentiator ADX-47273. ChemMedChem. 2009 Apr; 4(4): 505-11. PMID: 19197923, PMCID: PMC2865690, DOI: 10.1002/cmdc.200800357, ISSN: 1860-7187.

Delpire E, Days E, Lewis LM, Mi D, Kim K, Lindsley CW, Weaver CD. Small-molecule screen identifies inhibitors of the neuronal K-Cl cotransporter KCC2. Proc. Natl. Acad. Sci. U.S.A [print-electronic]. 2009 Mar 3/31/2009; 106(13): 5383-8. PMID: 19279215, PMCID: PMC2654392, PII: 0812756106, DOI: 10.1073/pnas.0812756106, ISSN: 1091-6490.

Conn PJ, Jones CK, Lindsley CW. Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Trends Pharmacol. Sci [print-electronic]. 2009 Mar; 30(3): 148-55. PMID: 19201489, PMCID: PMC2907736, PII: S0165-6147(09)00013-3, DOI: 10.1016/, ISSN: 0165-6147.

Marlo JE, Niswender CM, Days EL, Bridges TM, Xiang Y, Rodriguez AL, Shirey JK, Brady AE, Nalywajko T, Luo Q, Austin CA, Williams MB, Kim K, Williams R, Orton D, Brown HA, Lindsley CW, Weaver CD, Conn PJ. Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity. Mol. Pharmacol [print-electronic]. 2009 Mar; 75(3): 577-88. PMID: 19047481, PMCID: PMC2684909, PII: mol.108.052886, DOI: 10.1124/mol.108.052886, ISSN: 1521-0111.

Fadeyi OO, Lindsley CW. Rapid, general access to chiral beta-fluoroamines and beta,beta-difluoroamines via organocatalysis. Org. Lett. 2009 Feb 2/19/2009; 11(4): 943-6. PMID: 19159275, PMCID: PMC3192010, PII: 10.1021/ol802930q, DOI: 10.1021/ol802930q, ISSN: 1523-7052.

Scott SA, Selvy PE, Buck JR, Cho HP, Criswell TL, Thomas AL, Armstrong MD, Arteaga CL, Lindsley CW, Brown HA. Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. Nat. Chem. Biol [print-electronic]. 2009 Feb; 5(2): 108-17. PMID: 19136975, PMCID: PMC3798018, PII: nchembio.140, DOI: 10.1038/nchembio.140, ISSN: 1552-4469.

Williams R, Niswender CM, Luo Q, Le U, Conn PJ, Lindsley CW. Positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4). Part II: Challenges in hit-to-lead. Bioorg. Med. Chem. Lett [print-electronic]. 2009 Feb 2/1/2009; 19(3): 962-6. PMID: 19097893, PMCID: PMC3787871, PII: S0960-894X(08)01468-6, DOI: 10.1016/j.bmcl.2008.11.104, ISSN: 1464-3405.

Lindsley CW. Molecule of the month. FDA approves new treatment for fibromyalgia. Curr Top Med Chem. 2009; 9(2): 225. PMID: 19241619, ISSN: 1873-4294.

Conn PJ, Christopoulos A, Lindsley CW. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov. 2009 Jan; 8(1): 41-54. PMID: 19116626, PMCID: PMC2907734, PII: nrd2760, DOI: 10.1038/nrd2760, ISSN: 1474-1784.

Conn PJ, Lindsley CW, Jones CK. Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends Pharmacol. Sci [print-electronic]. 2009 Jan; 30(1): 25-31. PMID: 19058862, PMCID: PMC2907735, PII: S0165-6147(08)00247-2, DOI: 10.1016/, ISSN: 0165-6147.

Bridges TM, Williams R, Lindsley CW. Design of potent GlyT1 inhibitors: in vitro and in vivo profiles. Curr. Opin. Mol. Ther. 2008 Dec; 10(6): 591-601. PMID: 19051137, ISSN: 1464-8431.

Brady AE, Jones CK, Bridges TM, Kennedy JP, Thompson AD, Heiman JU, Breininger ML, Gentry PR, Yin H, Jadhav SB, Shirey JK, Conn PJ, Lindsley CW. Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats. J. Pharmacol. Exp. Ther [print-electronic]. 2008 Dec; 327(3): 941-53. PMID: 18772318, PMCID: PMC2745822, PII: jpet.108.140350, DOI: 10.1124/jpet.108.140350, ISSN: 1521-0103.

Niswender CM, Johnson KA, Weaver CD, Jones CK, Xiang Z, Luo Q, Rodriguez AL, Marlo JE, de Paulis T, Thompson AD, Days EL, Nalywajko T, Austin CA, Williams MB, Ayala JE, Williams R, Lindsley CW, Conn PJ. Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4. Mol. Pharmacol [print-electronic]. 2008 Nov; 74(5): 1345-58. PMID: 18664603, PMCID: PMC2574552, PII: mol.108.049551, DOI: 10.1124/mol.108.049551, ISSN: 1521-0111.

Lewis JA, Daniels RN, Lindsley CW. Total synthesis of Ciliatamides A-C: stereochemical revision and the natural product-guided synthesis of unnatural analogs. Org. Lett [print-electronic]. 2008 Oct 10/16/2008; 10(20): 4545-8. PMID: 18788742, PMCID: PMC3177603, DOI: 10.1021/ol801842v, ISSN: 1523-7052.

Miller NR, Daniels RN, Bridges TM, Brady AE, Conn PJ, Lindsley CW. Synthesis and SAR of analogs of the M1 allosteric agonist TBPB. Part II: Amides, sulfonamides and ureas--the effect of capping the distal basic piperidine nitrogen. Bioorg. Med. Chem. Lett [print-electronic]. 2008 Oct 10/15/2008; 18(20): 5443-7. PMID: 18829311, PMCID: PMC3177607, PII: S0960-894X(08)01088-3, DOI: 10.1016/j.bmcl.2008.09.032, ISSN: 1464-3405.

Bridges TM, Brady AE, Kennedy JP, Daniels RN, Miller NR, Kim K, Breininger ML, Gentry PR, Brogan JT, Jones CK, Conn PJ, Lindsley CW. Synthesis and SAR of analogues of the M1 allosteric agonist TBPB. Part I: Exploration of alternative benzyl and privileged structure moieties. Bioorg. Med. Chem. Lett [print-electronic]. 2008 Oct 10/15/2008; 18(20): 5439-42. PMID: 18805692, PMCID: PMC3177598, PII: S0960-894X(08)01078-0, DOI: 10.1016/j.bmcl.2008.09.023, ISSN: 1464-3405.

Niswender CM, Lebois EP, Luo Q, Kim K, Muchalski H, Yin H, Conn PJ, Lindsley CW. Positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4): Part I. Discovery of pyrazolo[3,4-d]pyrimidines as novel mGluR4 positive allosteric modulators. Bioorg. Med. Chem. Lett [print-electronic]. 2008 Oct 10/15/2008; 18(20): 5626-30. PMID: 18793851, PMCID: PMC3182458, PII: S0960-894X(08)01018-4, DOI: 10.1016/j.bmcl.2008.08.087, ISSN: 1464-3405.

Jones CK, Brady AE, Davis AA, Xiang Z, Bubser M, Tantawy MN, Kane AS, Bridges TM, Kennedy JP, Bradley SR, Peterson TE, Ansari MS, Baldwin RM, Kessler RM, Deutch AY, Lah JJ, Levey AI, Lindsley CW, Conn PJ. Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. J. Neurosci. 2008 Oct 10/8/2008; 28(41): 10422-33. PMID: 18842902, PMCID: PMC2577155, PII: 28/41/10422, DOI: 10.1523/JNEUROSCI.1850-08.2008, ISSN: 1529-2401.

Kennedy JP, Brogan JT, Lindsley CW. Total synthesis and biological evaluation of the marine bromopyrrole alkaloid dispyrin: elucidation of discrete molecular targets with therapeutic potential. J. Nat. Prod. 2008 Oct; 71(10): 1783-6. PMID: 18800848, DOI: 10.1021/np800339e, ISSN: 1520-6025.

Bridges TM, Lindsley CW. G-protein-coupled receptors: from classical modes of modulation to allosteric mechanisms. ACS Chem. Biol [print-electronic]. 2008 Sep 9/19/2008; 3(9): 530-41. PMID: 18652471, DOI: 10.1021/cb800116f, ISSN: 1554-8937.

Daniels RN, Fadeyi OO, Lindsley CW. A new catalytic Cu(II)/sparteine oxidant system for beta,beta-phenolic couplings of styrenyl phenols: synthesis of carpanone and unnatural analogs. Org. Lett [print-electronic]. 2008 Sep 9/18/2008; 10(18): 4097-100. PMID: 18729467, DOI: 10.1021/ol801643t, ISSN: 1523-7052.

Kim K, Miller NR, Sulikowski GA, Lindsley CW. A new multi-gram synthetic route to labeling precursors for the D(2/3) PET agent 18F-fallypride. Bioorg. Med. Chem. Lett [print-electronic]. 2008 Aug 8/15/2008; 18(16): 4467-9. PMID: 18674906, PMCID: PMC3177602, PII: S0960-894X(08)00840-8, DOI: 10.1016/j.bmcl.2008.07.065, ISSN: 1464-3405.

Sharma S, Rodriguez AL, Conn PJ, Lindsley CW. Synthesis and SAR of a mGluR5 allosteric partial antagonist lead: unexpected modulation of pharmacology with slight structural modifications to a 5-(phenylethynyl)pyrimidine scaffold. Bioorg. Med. Chem. Lett [print-electronic]. 2008 Jul 7/15/2008; 18(14): 4098-101. PMID: 18550372, PMCID: PMC2533619, PII: S0960-894X(08)00599-4, DOI: 10.1016/j.bmcl.2008.05.091, ISSN: 1464-3405.

Lewis JA, Lebois EP, Lindsley CW. Allosteric modulation of kinases and GPCRs: design principles and structural diversity. Curr Opin Chem Biol [print-electronic]. 2008 Jun; 12(3): 269-80. PMID: 18342020, PII: S1367-5931(08)00035-5, DOI: 10.1016/j.cbpa.2008.02.014, ISSN: 1367-5931.

Kennedy JP, Williams L, Bridges TM, Daniels RN, Weaver D, Lindsley CW. Application of combinatorial chemistry science on modern drug discovery. J Comb Chem [print-electronic]. 2008 May; 10(3): 345-54. PMID: 18220367, DOI: 10.1021/cc700187t, ISSN: 1520-4774.

Lindsley CW, Barnett SF, Layton ME, Bilodeau MT. The PI3K/Akt pathway: recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors. Curr Cancer Drug Targets. 2008 Feb; 8(1): 7-18. PMID: 18288939, ISSN: 1873-5576.

Lewis LM, Sheffler D, Williams R, Bridges TM, Kennedy JP, Brogan JT, Mulder MJ, Williams L, Nalywajko NT, Niswender CM, Weaver CD, Conn PJ, Lindsley CW. Synthesis and SAR of selective muscarinic acetylcholine receptor subtype 1 (M1 mAChR) antagonists. Bioorg. Med. Chem. Lett [print-electronic]. 2008 Feb 2/1/2008; 18(3): 885-90. PMID: 18178088, PMCID: PMC2275053, PII: S0960-894X(07)01510-7, DOI: 10.1016/j.bmcl.2007.12.051, ISSN: 1464-3405.

Lindsley CW. Molecule of the month. Curr Top Med Chem. 2008; 8(12): 1100. PMID: 18693392, ISSN: 1873-4294.

Lindsley CW. Is Zetia a 'do nothing' drug?. Curr Top Med Chem. 2008; 8(5): 434. PMID: 18399020, ISSN: 1873-4294.

Thomas AL, Lindsley CW. Molecule of the month. Overcoming resistance. Curr Top Med Chem. 2008; 8(1): 62. PMID: 18229423, ISSN: 1873-4294.

Lindsley CW. Molecule of the month. The 'skinny' on CB1 antagonists/inverse agonists: controversial obesity drugs will not go to FDA for approval. Curr Top Med Chem. 2008; 8(17): 1553. PMID: 19097323, ISSN: 1873-4294.

Lindsley CW. Tumor necrosis factor (TNF) blockers ignite FDA inquiry over cancer concerns. Curr Top Med Chem. 2008; 8(13): 1158. PMID: 18792455, ISSN: 1873-4294.

Yang ZQ, Barrow JC, Shipe WD, Schlegel KA, Shu Y, Yang FV, Lindsley CW, Rittle KE, Bock MG, Hartman GD, Uebele VN, Nuss CE, Fox SV, Kraus RL, Doran SM, Connolly TM, Tang C, Ballard JE, Kuo Y, Adarayan ED, Prueksaritanont T, Zrada MM, Marino MJ, Graufelds VK, DiLella AG, Reynolds IJ, Vargas HM, Bunting PB, Woltmann RF, Magee MM, Koblan KS, Renger J. Discovery of 1,4-substituted piperidines as potent and selective inhibitors of T-type calcium channels. J Med Chem. 2008; 51((20)): 6471-7.

Leslie N. Aldrich, Evan P. Lebois, L. Michelle Lewis, Natalia T. Nalywajko, Colleen M. Niswender, C. David Weaver, P. Jeffrey Conn, Craig W. Lindsley. MAOS protocols for the general synthesis and lead optimization of 3,6-disubstituted-[1,2,4]triazolo[4,3-b]pyridazines. Tetrahedron Letters. 2008; 50((2)): 212-5.

J. Phillip Kennedy, John T. Brogan, Craig W. Lindsley. Progress toward the synthesis of piperazimycin A: exploration of the synthesis of γ-hydroxy and γ-chloropiperazic acids. Tetrahedron Letters. 2008; 49((26)): 4116-8.

R. Nathan Daniels, Kwangho Kim, Evan P. Lebois, Hubert Muchalski, Mary Hughes, Craig W. Lindsley. Microwave-assisted protocols for the expedited synthesis of pyrazolo[1,5-a] and [3,4-d]pyrimidines. Tetrahedron Letters. 2008; 49((2)): 305-10.

Shipe WD, Barrow JC, Yang ZQ, Lindsley CW, Yang FV, Schlegel KA, Shu Y, Rittle KE, Bock MG, Hartman GD, Tang C, Ballard JE, Kuo Y, Adarayan ED, Prueksaritanont T, Zrada MM, Uebele VN, Nuss CE, Connolly TM, Doran SM, Fox SV, Kraus RL, Marino MJ, Graufelds VK, Vargas HM, Bunting PB, Hasbun-Manning M, Evans RM, Koblan KS, Renger JJ. Design, synthesis, and evaluation of a novel 4-aminomethyl-4-fluoropiperidine as a T-type Ca2+ channel antagonist. J Med Chem. 2008; 51((13)): 3692-5.

Zeng Z, O'Brien JA, Lemaire W, O'Malley SS, Miller PJ, Zhao Z, Wallace MA, Raab C, Lindsley CW, Sur C, Williams DL Jr. A novel radioligand for glycine transporter 1: characterization and use in autoradiographic and in vivo brain occupancy studies. Nucl Med Biol. 2008; 35((3)): 315-25.

Zhao Z, Wolkenberg SE, Lu M, Munshi V, Moyer G, Feng M, Carella AV, Ecto LT, Gabryelski LJ, Lai MT, Prasad SG, Yan Y, McGaughey GB, Miller MD, Lindsley CW, Hartman GD, Vacca JP, Williams TM. Novel indole-3-sulfonamides as potent HIV non-nucleoside reverse transcriptase inhibitors (NNRTIs). Bioorg Med Chem Lett. 2008; 18((2)): 554-9.

Zhao Z, Robinson RG, Barnett SF, Defeo-Jones D, Jones RE, Hartman GD, Huber HE, Duggan ME, Lindsley CW. Development of potent, allosteric dual Akt1 and Akt2 inhibitors with improved physical properties and cell activity. Bioorg Med Chem Lett. 2008; 18((1)): 49-53.

Lindsley CW, Weaver D, Jones C, Marnett L, Conn PJ. Preclinical drug discovery research and training at Vanderbilt. ACS Chem. Biol. 2007 Jan 1/23/2007; 2(1): 17-20. PMID: 17243778, DOI: 10.1021/cb6004867, ISSN: 1554-8937.

Lindsley CW, Barnett SF, Yaroschak M, Bilodeau MT, Layton ME. Recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors. Curr Top Med Chem. 2007; 7(14): 1349-63. PMID: 17692025, ISSN: 1873-4294.

Daniels RN, Lindsley CW. A new, non-SSRI mechanism of action for Prozac. Curr Top Med Chem. 2007; 7(10): 1039. PMID: 17563945, ISSN: 1873-4294.

Lindsley CW. Emerging from the shadow of Vioxx. Curr Top Med Chem. 2007; 7(7): 739. PMID: 17450647, ISSN: 1873-4294.

Lindsley, C.W.; Weaver, D.; Conn, P.J.; Marnett, L.. Preclinical Drug Discovery Research and Training at Vanderbilt. ACS Chem. Bio. 2007; 2((1)): 17-22.

Zhao, Z.; Wisnoski, D.D.; O’Brien, J.A.; Lemiare, W.; Williams, Jr., D.L.; Jacobson, M.A.; Wittman, M.; Ha, S.; Schaffhauser, H.; Sur, C.; Pettibone, D.J.; Duggan, M.E.; Conn, P.J.; Hartman, G.D.; Lindsley, C.W.. Challlenges in the development of mGluR5 positive allosteric modulators: the discovery of CPPHA. Bioorg. Med. Chem. Lett. 2007; 17: 1386-90.

Pawluczyk, J.M.; McClain, R.T.; Denicola, C.; Mulhearn, J.J.; Rudd, D.J.; Lindsley, C.W.. Microwave-initiated living free radical polymerization: Optimization of the preparative scale synthesis of Rasta resins’. Tetrahedron Lett. 2007; 48: 1497-501.

Lindsley, C.W.; Zhao, Z.; Leister, W.H.; OBrien, J.A.; Lemiare, W.; Williams, Jr., D.L.; Chen, T-B.; Chang, R.S.L.;Burno, M.; Jacobson, M.A.; Sur, C.; Kinney, G.G.; Pettibone, D.J.; Tiller,P.R.; Smith, S.;Tsou, N.N.; Duggan, M.E.; Conn, P.J.; Hartman, G.D.. Design, synthesis and in vivo efficacy of novel glycine transporter-1 (GlyT1) inhibitors derived from a series of [4-Phenyl-1-(propylsulfonyl)piperidin-4-yl] methyl benzamides. ChemMedChem. 2006; 1: 807-11.

Wolkenberg, S.E.; Zhao, Z.; Kapitskaya, M.; Webber, A.L.; Pertukhin, K.; Tang, Y.S.; Dean, D.C.; Hartman, George D.; Lindsley, C.W.. Identification of potent agonists of Photoreceptor-Specific Nuclear Receptor (NR2E3) and preparation of a radioligand. Bioorg. Med. Chem. Lett. 2006; 16: 5001-4.

Lindsley, C.W.; Shipe, W.D.; Wolkenberg, S.E.; Theberge, C.R.; Williams, D.L. Jr.; Sur, C.; Kinney, G.G.. Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia. Curr. Top. in Med. Chem. 2006; 6: 771-85.

Shipe, W.D.; Yang, F.; Zhao, Z.; Wolkenberg, S.E.; Nolt, M.B.; Lindsley, C.W.. Convenient and general microwave-assisted protocols for the expedient synthesis of heterocycles. Heterocycles. 2006; 70: 665-89.

Kausik,K.N.; Nolt, M.B.; Cato, M.J.; Kane, S.A.; Kiss, L.; Spencer, R.H.; Jixin Wang, J.; Lynch, J.L.; Regan, C.P.; Stump, G.L.; Li, B.;White, R.; Yeh, S.; Bogusky, M.J.; Bilodeau, M.T.; Dinsmore, C.J.; Lindsley, C.W.; Hartman, G.D.; Scott Wolkenberg S.E.;Trotter, B.W.. Potent antagonists of the atrial IKur/Kv1.5 potassium channel: synthesis and evaluation of analogous N,N- diisopropyl-2-(pyridine-3-yl)acetamides. Bioorg. Med. Chem.Lett. 2006; 16: 5897-5861.

Lindsley, C.W.;Wolkenberg, S.E.; Kinney, G.G.. Progress in the preparation and testing of glycine transporter type-1 (GlyT1) inhibitors. Curr. Topics in Med. Chem. 2006; 8: 1883-96.

Nolt, M.B.; Smiley, M.A.; Varga, S.L.; McClain, R.T.; Wolkenberg, S.E.; Lindsley, C.W.. Convenient preparation of substituted 5-amino oxazoles via a microwave-assisted Cornforth rearrangement. Tetrahedron. 2006; 62((Tetrahedron Symposia-in-Print MAOS invited)): 4698-704.

Lindsley, C.W.; Bogusky, M.J.; Leister, W.H.; McClain, R.T.; Robinson, R.; Barnett, S.F.; Defeo-Jones, D.; III Ross, C.W.; Hartman, G.D.. Synthesis and biological evaluation of unnatural canthine alkaloids. Tetrahedron Lett. 2005; 46: 2779-82.

Lindsley, C.W.; Zhao, Z.; Leister, W.H.; Robinson, R.G.; Barnett, S.F.; Defeo-Jones, D.; Jones, R.E.; Hartman, G.D.; Huff, J.R.; Huber, H.E.; Duggan, M.E.. Allosteric Akt (PKB) kinase inhibitors. Discovery and SAR of isozyme selective inhibitors. Bioorg. Med. Chem. Lett. 2005; 15: 761-4.

Kim, D.; Cheng, G.Z.; Lindsley, C.W.; Yang, H.; Cheng, J.Q.. The Akt/PKB pathway: molecular target for cancer therapy. Oncogene. 2005; 24: 7482-92.

Defeo-Jones, D.; Barnett, S.F.; Fu, S.; Hancock, P.J.; Haskell, K.M.; Leander, K.R.; McAvoy, E.; Robinson, R.G.; Duggan, M.E.; Lindsley, C.W.; Zhao, Z.; Huber, H.E.; Jones, R.E.. Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members. 2005; 4: 271-8.

Kinney, G.G.; O’Brien, Lemaire, W.; Burno, M.’ Bickel, D.J.; Clements, M.K.; Wisnoski, D.D.; Lindsley, C.W.; Tiller, P.R.; Smith, S.; Jacobson, M.A.; Sur, C.; Duggan, M.E.; Pettibone, D.J.; Williams, Jr., D.W.. A novel selective allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5) has an antipsychotic profile in rat behavioral models. J. Pharmacol. Exp. 2005; 313: 199-211.

Lindsley, C.W.; Wisnoski, D.D.; Leister, W.H.;; O'Brien, J.A.; Lemiare, W.; Williams, Jr., D.L.; Burno, M.; Sur, C.; Kinney, G.G.; Pettibone, D.J.; iller, P.R.; Smith, S.; Duggan, M.E .; Hartman, G.D.; Conn, P.J.; Huff, J.R.. Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3-Diphenyl-1H-pyrazol-5-yl)benzamides that potentiate receptor function in vivo. J. Med.Chem. 2004; 47: 5825-8.

Available Postdoctoral Position Details
Posted: 12/17/2015
Postdoc position available - drug discovery/lead optimization. Develop small molecule screening leads into proof of concept compounds to validate new targets/mechanisms in animal models. Work closely with colleagues in pharmacology. Some organic chemistry experience is required.